Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.
Inside 340B Report
Claim This Podcastby 340B Report
5.0(4 reviews)
42 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
33
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality53
Social0
YouTube0
Engagement32
Podcast Overview
Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.
Language
🇺🇲
Publishing Since
9/3/2024
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
33
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality53
Social0
YouTube0
Engagement32
6
Excellent Areas
2
Good Performance
11
Growth Opportunities
excellent
Episode Length
31 minutes
Performing excellently!
good
Publishing Consistency
Every 15 days
Recommendations available
Unlock the full report to see detailed tips
poor
Episode Thumbnails
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Inside 340B Report
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
June 5, 2026
Episode 41: Lilly's 340B In-House Claims Ultimatum, 1st Circuit Oral Arguments and Primary Results
<p class="MsoNormal"><span lang="EN" xml:lang="EN">In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: Eli Lilly's 340B in-house claims data threat and a leading provider law firm's response; high-stakes oral arguments over two states' contract pharmacy laws; and the results from primaries involving high-profile 340B advocates. The team also recaps 340B Report's recent webinar on key 340B legal issues.</span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">Key Topics Covered:</span></strong></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">Lilly's In-House Claims Data Ultimatum </span></strong></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Luke highlights two recent letters sent to the Health Resources and Services Administration: one from Lilly and one from Hall Render, a law firm representing 340B providers. Lilly notified covered entities they had five days to comply with its 340B in-house pharmacy claims data submission policy, while Hall Render called for a U.S. Department of Health and Human Services Inspector General investigation into Lilly's requirements. Shannon notes that Sanofi recently announced 340B in-house claims data requirements, making it the ninth drugmaker to do so.<span style= "mso-spacerun: yes;"> </span></span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">Latest Primary Results</span></strong></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Shannon breaks down early results from June primary contests in California and South Dakota. She notes that U.S. Rep. Doris Matsui (D-Calif.), who is seen as a key 340B provider advocate in Congress, placed first in her primary. But, Shannon adds, she is likely to once again face off against a tough Democratic challenger, Mai Vang, in November. Shannon also discusses U.S. Rep. Dusty Johnson's (R-S.D.) third place finish in South Dakota's GOP gubernatorial primary, and how the loss of another key 340B leader on Capitol Hill could shape 340B policymaking in the next Congress.</span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">Oral Arguments and 340B Report Webinar</span></strong></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Will discusses recent oral arguments on drugmaker challenges to Maine and Rhode Island's 340B contract pharmacy access laws before a Boston federal appeals court. He notes that one of the judges last year was a partner at a law firm where other partners were lobbying for a drug industry trade group against Maine's contract pharmacy bill before it became law. Will, Luke and Ted then break down the biggest takeaways from 340B Report's recent subscriber-only webinar, where two attorneys representing the covered entity and manufacturer perspectives joined 340B Report's editorial team to discuss the biggest 340B legal developments.</span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang= "EN">Subscribe & Stay Updated</span></strong></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">How to Follow Us and Learn More About This Episode's Sponsor</span></strong></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Stay tuned for more episodes every other week! </span><span lang="EN" style= "font-family: REM; mso-fareast-font-family: REM; mso-bidi-font-family: REM;" xml:lang="EN">🎧</span><span lang="EN" xml:lang="EN">Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.</span></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Each episode is brought to you by one of our great Ultra Diamond sponsors, <a href="https://www.pillrhealth.com/"><span style= "color: #1155cc;">Pillr Health</span></a>. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship.<span style= "mso-spacerun: yes;"> </span></span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang= "EN">Subscribe to 340B Report with a Special Discount</span></strong></p> <p><span lang="EN" style= "font-size: 12.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-ansi-language: EN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;" xml:lang="EN">We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href="https://340breport.com/subscribe/"><span style= "color: #0563c1;">subscribe now</span></a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319"><span style="color: #0563c1;"> free trial</span></a>.</span></p>
May 22, 2026
Episode 40: Big Congressional Primary Losses, G6 Back to Six and Another New Dark Money Campaign
<p>In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including two high-profile 340B detractors' recent GOP U.S. Senate primary election losses, the newest member of a Senate bipartisan working group focused on 340B reform, a new dark money effort seeking to influence the 340B rebate debate and contract pharmacy access bills in Minnesota and Illinois. They also tease 340B Report's upcoming June 3 webinar.</p> <p><strong>Key Topics Covered:</strong></p> <p><strong>Congressional Losses and an Addition</strong> <br /> Shannon breaks down U.S. Sen. Bill Cassidy (R-La.) and U.S. Rep. Earl "Buddy" Carter's (R-Ga.) recent GOP primary losses in two key Senate races and what the loss of the two high-profile 340B critics and advocates for change could mean for the program in the next Congress. Ted provides important historical context on Cassidy and Carter's legacies on 340B issues in Congress, as well as the losses and their highly consequential ramifications. Shannon also discusses U.S. Sen. John Boozman's (R-Ark.) addition to the "group of six" (G6) senators behind high-profile 340B program legislation, known as the "SUSTAIN 340B Act," including his record of supporting 340B providers in Congress.</p> <p><strong>Dark Money Campaign Emerges</strong> <br /> Will discusses his latest scoop on a new dark money effort pressuring congressional Republicans to support a 340B rebate model. He explains that an Austin, Texas-based nonprofit with undisclosed donors and ties to a Washington, D.C. lobbying firm recently launched a new advocacy campaign promoting 340B rebates. Will provides exclusive details on this effort and whether it will affect the ongoing 340B rebate debate.</p> <p><strong>State Updates and a 340B Report Webinar</strong><br /> Will discusses Minnesota state legislators' failed effort to pass legislation to strengthen the state's existing 340B contract pharmacy law in the final days of the state session—despite it passing the state Senate and having bipartisan backers in the state House. He also discusses an ongoing battle over 340B contract pharmacy access legislation in Illinois.</p> <p>Will then previews 340B Report's exclusive, subscriber-only webinar, which will take place June 3 at 1 p.m. ET. Attorneys representing the covered entity and drugmaker perspectives will join 340B Report's editorial team to break down ongoing litigation over state 340B contract pharmacy access laws, as well as potential new legal pathways for covered entities to challenge alleged overcharge violations. You can learn more about the webinar here. </p> <p><strong>Subscribe & Stay Updated</strong></p> <p><strong>How to Follow Us and Learn More About This Episode's Sponsor</strong></p> <p>Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.</p> <p>Each episode is brought to you by one of our great Ultra Diamond sponsors. <a href="https://verity-solutions.com/">Verity Solutions</a>' innovative, award-winning 340B program management solutions are designed to optimize 340B pharmacy spend and maximize pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. </p> <p><strong>Subscribe to 340B Report with a Special Discount</strong></p> <p>We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href= "https://340breport.com/subscribe/">subscribe now</a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319">free trial</a>.</p>
May 11, 2026
Episode 39: New 340B Congressional Scrutiny, Another PhRMA Ad Blitz and a Louisiana Update
<p class="MsoNormal"><span lang="EN" xml:lang="EN">In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki break down the latest in 340B news, including recent congressional hearings and letters that focused on the 340B program, a major drug industry trade group's new seven-figure ad campaign targeting 340B hospitals and the Louisiana attorney general's moves to enforce the state's 340B contract pharmacy access law.</span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">Key Topics Covered:</span></strong></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">Congress Weighs In</span></strong></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Shannon breaks down two recent congressional hearings where the 340B program drew scrutiny from witnesses and lawmakers—a May 5 U.S. Senate Health, Education, Labor and Pensions (HELP) Committee field hearing in Louisiana and an April 28 U.S. House Ways and Means Committee hearing. She notes that U.S. Sen. Bill Cassidy (R-La.), who chairs the HELP Committee and faces a tough upcoming GOP primary challenge, did not say much about the 340B program at his panel's field hearing despite his investigation into the program and previous vocal calls for reform. However a witness, who leads a private cancer clinic, focused her attention on 340B and called for major changes. A Louisiana independent pharmacist also weighed in. Meanwhile, Will discusses competing congressional letters that supported and opposed federal efforts to implement a 340B rebate model. And Luke dives into an expected bipartisan bill that will exempt additional covered entities from rebates. He notes that while the bill has not been introduced yet, 340B Report got an exclusive look at its contents.</span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">PhRMA Launches New Campaign </span></strong></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Shannon discusses the Pharmaceutical Research and Manufacturers of America's (PhRMA) newest seven-figure ad blitz that takes aim at 340B hospitals. She notes that the campaign, which follows a similar 2025 seven-figure effort from PhRMA, argues that "340B medicine markups are a goldmine for big hospital systems" and features a video ad depicting fictional hospital leaders at a "340B executive spa." Shannon also discusses how key hospital trade groups, including the American Hospital Association, responded to PhRMA's ad campaign.</span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">Key Legal Developments</span></strong></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Will discusses the Louisiana attorney general's (AG) plans to take enforcement action against manufacturers for alleged violations of the state's 340B contract pharmacy access law. He notes that the move comes roughly three months after a three-judge panel for a New Orleans federal appeals court unanimously upheld the state law against multiple drugmaker legal challenges. And it came as the AG said she's received numerous complaints about alleged violations of the law. Will explains that Louisiana was the second state in the nation to enact a contract pharmacy law, following Arkansas, which similarly took enforcement action following a legal victory.</span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang= "EN">Subscribe & Stay Updated</span></strong></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang="EN">How to Follow Us and Learn More About This Episode's Sponsor</span></strong></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Stay tuned for more episodes every other week! </span><span lang="EN" style= "font-family: REM; mso-fareast-font-family: REM; mso-bidi-font-family: REM;" xml:lang="EN">🎧</span><span lang="EN" xml:lang="EN">Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.</span></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">Each episode is brought to you by one of our great Ultra Diamond sponsors. <a href="https://www.nuvemrx.com/"><span style= "color: #1155cc; background: white; mso-highlight: white;">NuvemRx</span></a> <span style="background: white; mso-highlight: white;">empowers covered entities to turn 340B from a compliance burden into a strategic asset with a full suite of TPA, in-house pharmacy and referral solutions.</span> Learn more at www.nuvemrx.com. We are very grateful to NuvemRx for its sponsorship.</span></p> <p class="MsoNormal"><strong><span lang="EN" xml:lang= "EN">Subscribe to 340B Report with a Special Discount</span></strong></p> <p><span lang="EN" style= "font-size: 12.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-ansi-language: EN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;" xml:lang="EN">We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href="https://340breport.com/subscribe/"><span style= "color: #0563c1;">subscribe now</span></a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319"><span style="color: #0563c1;"> free trial</span></a>.</span></p>
42 total episodes available
Similar Podcasts
Discover related shows you might enjoy
340B Unscripted
SpendMend Pharmacy
340B 360
340B Report
340B Insight
340B Health
340Banter Podcast
FQHC 340B Compliance
340B Pulse
NorthArcHealth
Fresh Air
NPR
I Will Teach You To Be Rich
Ramit Sethi
The Daily
The New York Times
KFF Health News' 'What the Health?'
KFF Health News
The Indicator from Planet Money
NPR
The Daily Show: Ears Edition
Comedy Central
Planet Money
NPR
Good Hang with Amy Poehler
The Ringer
TED Radio Hour
NPR
Dare to Lead with Brené Brown
Vox Media Podcast Network
Deep-dive analytics for Inside 340B Report
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Inside 340B Report?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.